• Gross sales of approximately $25 million AUD reached since January 2025 with monthly increases
• Total prescriptions grew monthly, reaching over 16,000 across 6,700 patients
• Patients enrolled in auto-refill program had a 95% adherence rate, 79% amongst all patients

Botanix Pharmaceuticals Ltd has provided an update on the launch of its product Sofdra, reporting strong financial and operational performance. The company reached gross sales of approximately $25 million AUD since January 2025, with increases month over month. Total prescriptions grew monthly, reaching over 16,000 prescriptions filled across 6,700 patients from launch to 30 June 2025. Patients enrolled in the auto-refill program had a 95% adherence rate, a measure of how consistently patients obtain refills for their prescribed medications. The overall adherence rate amongst all patients was 79%. The company has confirmed that it is in compliance with the ASX Listing Rules, particularly Rule 3.1 regarding continuous disclosure obligations.

Botanix Pharmaceuticals Ltd reported gross sales of approximately $25 million AUD since January 2025, with monthly increases, and total prescriptions reaching over 16,000 across 6,700 patients from launch to 30 June 2025.